Tirzepatide
In the tracked data, 30 of 30 EU+ jurisdictions list authorised or limited status for Tirzepatide. This page summarises approval status, brands, shortages and recent regulatory changes by country.
Related regulatory compounds
Country-by-country approval and availability
30 EU+ jurisdictions covered.
Updates for Tirzepatide
2025-12-11 · 🇪🇺 EU
EMA CHMP: positive opinion on Mounjaro® marketing authorisation variation
On 11 December 2025 EMA's CHMP adopted a positive opinion recommending a change to the marketing authorisation terms for Mounjaro® (tirzepatide) at EU level.
2025-09-01 · 🇬🇧 United Kingdom
NICE TA1026: commercial arrangement added for Mounjaro® in weight management
September 2025: NICE added the commercial arrangement to the TA1026 recommendation and updated tirzepatide pricing for overweight/obesity management on the NHS.
2025-05-12 · 🇪🇺 EU
EASO: semaglutide & tirzepatide as first-line obesity treatment
The European Association for the Study of Obesity (EASO) issued new framework recommending semaglutide and tirzepatide as first-line pharmacotherapy for obesity and most of its complications.
2025-01-15 · 🇬🇧 United Kingdom
Mounjaro® available via NHS for weight management
NICE approved rollout for weight management with phased access over the next 3 years.
2024-07-01 · 🇬🇷 Greece
Mounjaro® launches in Greece
Official launch of 2.5/5/7.5/10/12.5/15mg in Greek pharmacies with EOPYY for T2D.